Latest Regulatory Clearance News

Qoria Limited is moving towards a transformative merger with US-based Aura Consolidated Group, Inc., combining complementary digital safety platforms and targeting growth through a $100 million capital raise and ASX listing.

EMVision's First Responder Brain Scanner has proven its operational feasibility in aeromedical settings with the Royal Flying Doctor Service, de-risking rural stroke diagnosis and supporting progression to commercial production.

Bremworth's acquisition by Floorscape faces further delay as the New Zealand Commerce Commission extends its clearance deadline to 30 June 2026, pushing the deal close to its expiry date.

Pacific Nickel Mines is pressing ahead with the sale of its Kolosori Nickel Project for a nominal A$1 while remaining suspended from the ASX, supported by ongoing Glencore financing and subject to key approvals.

Osteopore has secured Hainan FDA approval to clinically use and sell its custom orthopaedic devices at Shanghai Ruijin Hospital’s Hainan branch, marking a key step towards wider China market access. The company has scheduled its first patient surgery for June 2026.

SDI Limited has dispatched its Scheme Booklet to shareholders as it moves closer to a $1.40 per share acquisition by a Beijing Guoci subsidiary. The virtual shareholder meeting is set for 22 June 2026 with strong backing from the board and largest shareholder.

Tuas Limited has called off its planned acquisition of M1 Limited after failing to meet critical conditions by the extended deadline, while regulatory scrutiny intensifies around its subsidiary Simba Telecom.

4DMedical’s CT:VQ™ technology has been clinically validated in a top respiratory journal, showing a leap in patient response rates for lung volume reduction surgery from 46% to 76%, promising improved outcomes and hospital efficiencies.

Advanced Innergy Holdings secures Foreign Investment Review Board approval for its full acquisition of Matrix Composites & Engineering, clearing a major regulatory hurdle and setting the stage for shareholder votes on the $0.40 per share scheme.

Australian Strategic Materials Limited (ASM) shareholders are set to vote on a scheme of arrangement for Energy Fuels Inc. to acquire 100% of ASM shares and options, offering a significant premium and exposure to a vertically integrated rare earth supply chain.

Lumos Diagnostics advances US commercial rollout of FebriDx with positive reimbursement data and expanded urgent care adoption ahead of the 2027/28 flu season.

AVITA Medical reported a 4% revenue increase in Q1 2026 with a narrowed net loss, underpinned by a new BARDA contract and promising Cohealyx clinical data. Leadership changes and regulatory approvals support a confident outlook.